Apreo Health® Announces Presentation of Clinical Data from the BREATHE 1&2 Trials at ATS 2025 and Publication of Six-Month Data in American Journal of Respiratory and Critical Care Medicine
Apreo Health, a clinical-stage medical device company developing a novel, tissue-sparing treatment for severe emphysema, today announced the presentation of first-in-human six-month clinical data from the BREATHE 1&2 trials in a late-breaking abstract session at the American Thoracic Society (ATS) 2025 International Conference in San Francisco. The study was simultaneously published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).
Apreo Health to Present First-in-Human Data for Novel Airway Scaffold in Late-Breaking Abstract at ATS 2025
Apreo Health, a clinical-stage medical device company developing a novel, tissue-sparing treatment for severe emphysema, today announced its emergence from stealth and upcoming presentation of first-in-human clinical data at the American Thoracic Society (ATS) 2025 International Conference, May 16-21 in San Francisco. The company’s BREATHE 1&2 feasibility studies will be presented as a late-breaking abstract on Monday, May 19.
